ADC Antibody Development

Based on “Integrated and Innovative Antibody-drug Conjugates R&D Platform” and “Super Trillion Antibody Library Platform”, we can customize the screening of the best antibody suitable for ADC drug development for partners, and can also provide overall R&D services for ADC drugs from target to Pre-clinical candidates.


Service Highlights

1. Integrated platform for innovative ADC discovery

  • 10 functional modules and 40+ sub-platforms cover the whole antibody discovery process.

  • Professional project management system, seamless integration among all modules, and high efficiency for PCC completion (12 months).

2. Unique multi-pathway antibody generation platform

  • Seven trillion large-capacity antibody library, thousands of lead molecules for conventional targets can be obtained.

  • Diverse antibody sources: natural B-cell antibodies, B-cell rearranged antibodies, synthetic and semi-synthetic antibodies, mouse immunization library, alpaca immunization library.

  • Full coverage of molecular formats: full antibodies, single domain antibodies, bispecific antibodies, mouse monoclonal antibodies, rat monoclonal antibodies.

3. Rapid & high-throughput conjugation platform

  • High-throughput, stable and controlled conjugation platform for efficient screening of lead antibodies.

  • Multiple conjugation methods evaluation: flexible combination of payloads and linkers.

4. Experienced & professional research team

  • 20+ scientists in various fields, systematic and scientific project development.

  • 100+ projects development experience, high rate for successful project deliver.

5. Flexible customization services

  • Customized innovative ADC R&D with diversified service forms.

  • Flexible combination of ADC three core elements to suit different R&D needs.

Popular articles

Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more
Shanghai Model Organisms Jinshan R&D Base officially put into operation

After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.

Learn more